Estudio de masa de riñón experto - Atlanta, GA

Evaluación de masas renales

Evaluación integral del riñón mediante imágenes médicas avanzadas, pruebas genómicas y experiencia multidisciplinaria para crear planes de tratamiento personalizados.

Schedule consultationCall 678-344-8900
✓
Comprehensive imaging with CT, MRI, and ultrasound
✓
Percutaneous biopsy for pathologic diagnosis when needed
✓
Risk stratification to guide surgery, ablation, or surveillance

¿Qué son las masas renales?

A renal mass is any abnormal growth in the kidney discovered on imaging. Most are found incidentally during scans for unrelated symptoms. Renal masses can be:

  • Benign: Simple cysts, angiomyolipomas, oncocytomas (20-30% of solid masses)
  • Malignant: Renal cell carcinoma (RCC) — the most common kidney cancer in adults
  • Indeterminate: Require further workup to clarify nature and appropriate management

Estudio inicial de imágenes

Tomografía computarizada con contraste

Gold standard for characterizing renal masses. Shows:

  • Size, location, and growth pattern
  • Enhancement (suggests solid tumor vs. cyst)
  • Involvement of blood vessels, lymph nodes, or adjacent organs
  • Chest imaging included to screen for metastases

resonancia magnética

Used when:

  • Patient has contrast allergy or kidney disease
  • Equivocal findings on CT requiring further characterization
  • Superior for characterizing cystic lesions (Bosniak classification)
  • Assessing tumor thrombus in renal vein or IVC

Clasificación bosnia (para masas quísticas)

  • Bosniak I: Simple cyst; no follow-up needed
  • Bosniak II: Minimally complex; annual imaging surveillance
  • Bosniak IIF: Moderately complex; close follow-up every 6 months
  • Bosniak III: Indeterminate; 50% cancer risk — biopsy or surgery recommended
  • Bosniak IV: Clearly malignant; surgical excision indicated

Biopsia masiva renal

Cuando recomendamos la biopsia

  • Small masses (<4 cm) being considered for active surveillance or ablation
  • Metastatic disease where tissue diagnosis is needed before systemic therapy
  • Atypical imaging features (suspected lymphoma, abscess, metastasis to kidney)
  • Clinical trial enrollment requiring pathologic confirmation

El Procedimiento

  • Outpatient, conscious sedation
  • CT or ultrasound-guided needle biopsy
  • 15-20 minutes; minimal discomfort
  • Results in 3-5 days; includes histology and molecular profiling
  • Diagnostic accuracy >90% with modern techniques

Estratificación de riesgos y planificación del tratamiento

We integrate imaging, biopsy, patient age, comorbidities, and preferences to recommend:

  • Active Surveillance: For small (<2 cm), slow-growing masses in elderly or high-risk surgical patients
  • Ablation: For T1a tumors (<4 cm) in select patients wanting kidney-sparing minimally invasive options
  • Robotic Partial Nephrectomy: Gold standard for T1 tumors; preserves kidney function
  • Radical Nephrectomy: For large, complex, or locally advanced cancers
  • Systemic Therapy: For metastatic disease (immunotherapy, targeted therapy, clinical trials)

Vigilancia de seguimiento

After treatment (or if on active surveillance), we monitor with:

  • CT or MRI at regular intervals (every 3-6 months initially, then annually)
  • Chest imaging to detect lung metastases (most common site of spread)
  • Lab work (creatinine to assess kidney function, CBC)
  • Longer follow-up for high-grade tumors (5-10 years minimum)
  • Patients on active surveillance undergo imaging every 3-6 months to detect growth requiring intervention

¿Por qué Urología Avanzada?

  • Fellowship-trained kidney cancer specialists with expertise in imaging interpretation and risk stratification
  • In-house biopsy capabilities with rapid pathology turnaround and molecular profiling
  • Multidisciplinary tumor boards reviewing every complex case to ensure optimal treatment selection
  • Access to advanced therapies — robotic surgery, thermal and non-thermal ablation, immunotherapy, targeted therapy, clinical trials
  • Personalized surveillance protocols tailored to your individual risk profile and preferences

Preguntas frecuentes

¿Todas las masas de riñón son cancerosas?

No. About 20-30% of solid masses are benign. Simple cysts are extremely common and almost never cancerous. Biopsy and advanced imaging help distinguish benign from malignant.

¿Debería buscar una segunda opinión?

Yes, especially for complex or large masses. We welcome second opinions and routinely review outside imaging and pathology to ensure accurate diagnosis and optimal treatment planning.

¿Qué tan rápido crecen los tumores de riñón?

Most renal cell carcinomas grow slowly (2-5 mm per year on average). This allows time for thorough evaluation and informed decision-making. Aggressive tumors grow faster and require prompt intervention.

¿Puedo esperar y ver una pequeña misa?

Yes, for select patients. Active surveillance is safe for small (<2 cm), slow-growing masses in elderly patients or those with significant comorbidities. Close imaging follow-up ensures intervention if growth occurs.

Próximos pasos

If you have been diagnosed with a kidney mass or have concerning findings on imaging, our kidney cancer specialists will provide comprehensive evaluation, explain all treatment options, and create a personalized plan focused on cancer control and preserving kidney function.

Schedule evaluationEmail our team